Clinical metabolomics research on Xiaozhang Tie with the umbilical compress therapy for cirrhotic ascites
10.16438/j.0513-4870.2020-1357
- VernacularTitle:消胀贴膏敷脐治疗肝硬化腹水的临床代谢组学研究
- Author:
Ze-hui HE
1
;
Kai ZHANG
2
;
Tao YANG
3
;
Feng XING
3
;
Cheng-hai LIU
3
;
Yong-tai ZHANG
1
;
Zhen-da LIU
1
;
Nian-ping FENG
1
Author Information
1. School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
3. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
- Publication Type:Research Article
- Keywords:
metabolomics;
cirrhotic ascites;
Xiaozhang Tie;
biomarker;
clinical research
- From:
Acta Pharmaceutica Sinica
2021;56(1):257-265
- CountryChina
- Language:Chinese
-
Abstract:
We used metabolomics technology to identify and understand the biomarkers and therapeutic mechanisms of umbilical compress therapy based on Xiaozhang Tie (XT) to provide scientific evidence for its clinical application. A total of 10 patients with cirrhotic ascites and gastrointestinal motility disorders who were hospitalized in the Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from November 2017 to June 2018 were divided into a placebo group (4 cases) or an XT group (5 cases), and 10 healthy volunteers were included as controls. This clinical trial was approved according to the Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (2017-528-11-01). The patients in the XT group were given umbilical compress therapy with Xiaozhang Tie, and patients in the placebo group were administered a plaster patch in which the drug content was less than 5%, receiving one patch per day for three consecutive days. Non-targeted metabolomics technology and UPLC-Q/Orbitrap-MS/MS analysis technology were utilized to investigate the fluctuations in endogenous metabolic profiles in the patient's urine prior to and after administration of XT. By analyzing and comparing the urine metabolic profiles of patients with cirrhotic ascites to those of healthy volunteers, a total of 31 biomarkers were identified, 14 of which were significantly decreased by the intervention with Xiaozhang Tie (P <0.05). Pathway enrichment analysis revealed that phenylalanine metabolism and tryptophan metabolism are key pathways affected by XT treatment. The results suggest that XT can alleviate cirrhotic ascites by modulating abnormalities in amino acid metabolism.
